What Is Nyxoah SA (NYXH) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Nyxoah SA currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.
What Do the Models Say About NYXH?
0 of 13 models are currently active for NYXH. See which stocks rank higher →
How Does NYXH Rank in Medical Instruments & Supplies?
Among 56 Medical Instruments & Supplies stocks, NYXH ranks #44 by Quality of Company score. CirclFi's QOC score of 5.6/10 evaluates 32 fundamental signals. A score of 5.6 reflects mixed fundamentals.
See all Most Undervalued Medical Instruments & Supplies Stocks →
Nyxoah SA operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.
Is NYXH a Value Trap?
CirclFi's Value Trap algorithm assigns NYXH a score of 38/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
0 of 13 models are active for Nyxoah SA. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Nyxoah SA's fundamental quality profile registers 5.6/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every NYXH valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →